SCHEMBL6792767

SCHEMBL6792767

CC(=O)c1cccc(-c2ccccc2C(=O)O)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UCHL5 Q9Y5K5 1/20 0.54
DDT P30046 1/20 0.50
KDM4C Q9H3R0 1/20 0.50
HNF4A P41235 1/20 0.50
EIF4E P06730 1/20 0.49
AKR1C3 P42330 3/20 0.49
AKR1C2 P52895 3/20 0.49
FOLH1 Q04609 1/20 0.49
AKR1B10 O60218 1/20 0.49
AKR1B1 P15121 1/20 0.49
AKR1C4 P17516 1/20 0.49
AKR1C1 Q04828 1/20 0.49
MYC P01106 1/20 0.49
KMO O15229 1/20 0.49
NR1H4 Q96RI1 1/20 0.48
MAPT P10636 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
ACLY P53396 1/20 0.47
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29952530 1.00 UCHL5 (0.54) UCHL5DDTKDM4CHNF4AEIF4E
SCHEMBL29400093 0.88 KMO (0.63) UCHL5DDTKDM4CHNF4AAKR1C3
SCHEMBL2947834 0.88 KMO (0.63) UCHL5DDTKDM4CHNF4AAKR1C3
SCHEMBL2556585 0.87 NR1H4 (0.46) UCHL5DDTHNF4AEIF4EAKR1C3
SCHEMBL4264467 0.87 KDM4C (0.66) UCHL5DDTKDM4CFOLH1KMO
SCHEMBL1449798 0.86 MAPT (0.53) AKR1C3AKR1C2KMONR1H4MAPT
SCHEMBL2579535 0.86 EIF4E (0.49) UCHL5DDTHNF4AEIF4EAKR1C3
SCHEMBL2456422 0.84 S100A4 (0.55) AKR1C3AKR1C2KMONR1H4MAPT
SCHEMBL689031 0.84 HNF4A (0.62) UCHL5HNF4AFOLH1MYCKMO
SCHEMBL27361722 0.83 BCAT2 (0.58) UCHL5DDTHNF4AFOLH1MYC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US disclosed
EP-1326835-A1 BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-07-16 EP disclosed
WO-2002028835-A1 BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 UCHL5 1881/4885DDT 3173/4885KDM4C 3679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.